

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

**Multiple Technology Appraisal (MTA)**

**Follicular lymphoma - rituximab (review)**

**Response to consultee and commentator comments on the provisional matrix of consultees and commentators**

<b>Version of matrix of consultees and commentators reviewed:</b>				
Provisional matrix of consultees and commentators sent for consultation				
<b>Summary of comments, action taken, and justification of action:</b>				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>Consultees and Commentators did not provide any comments on the provisional matrix during the scoping consultation</i>	<i>NICE Secretariat</i>	<i>Noted</i>	

2.	<i>Care Quality Commission</i>	<i>NICE Secretariat</i>		<i>Added</i>	<i>Care Quality Commission are added to all matrices.</i>
3.	<i>Cancer 52</i>	<i>NICE Secretariat</i>		<i>Added</i>	<i>Cancer 52 are added to all matrices, where the topic covers cancer.</i>
4.	<i>National Cancer Alliance</i>	<i>NICE Secretariat</i>		<i>Removed</i>	<i>National Cancer Alliance would no longer like to be a consultee on any topics.</i>

5.	<i>National Council for Palliative Care</i>	<i>NICE Secretariat</i>		<i>Removed</i>	<i>National Council for Palliative Care would no longer like to be a consultee on any topics.</i>
6.	<i>Rarer Cancers Forum</i>	<i>NICE Secretariat</i>		<i>Added</i>	<i>Rarer Cancers Forum are added to all matrices, where the topic covers rare cancer's.</i>